Marking Immutep’s transition to a Phase III biotech, the Company’s pivotal TACTI-004 trial in first-line non-small cell lung cancer (1L NSCLC) received first regulatory approval Mature data from ...

Marking Immutep’s transition to a Phase III biotech, the Company’s pivotal TACTI-004 trial in first-line non-small cell lung cancer (1L NSCLC) received first regulatory approval Mature data ...

SYDNEY, Australia - Immutep Limited (NASDAQ:IMMP), a biotechnology company specializing in pharmaceutical preparations with a market capitalization of $285 million, has disclosed its quarterly ...

Shares in Immutep have leapt after the biotech reported phase 2b results showing that LAG-3 inhibitor eftilagimod alfa (efti) significantly boosted the efficacy of MSD’s Keytruda in patients ...

Marking Immutep's transition to a Phase III biotech, the Company's pivotal TACTI-004 trial in first-line non-small cell lung cancer (1L NSCLC) received first regulatory approval Mature data from ...

Immutep Limited announced significant advancements in its clinical programs for LAG-3 immunotherapies in a press release detailing their activities for the quarter ended December 31, 2024. The ...

In this article, we are going to take a look at where Immutep Limited (NASDAQ:IMMP) stands against the other long term ASX stocks. Vanguard believes that Australia's economy remains well-placed to ...